Biotech Values

[DewDiligence]

MNTA: What is M178? (patent-expiration table for biologics)

From the 2006 PR announcing the FoB collaboration with Sandoz (#msg-12222305):

“The product candidates in the collaboration will all leverage Momenta's characterization technology, which enables the detailed chemical sequencing and analysis of complex mixtures. Momenta's goal is to apply its technology to create generic and follow-on versions of complex drugs and biologics, which have been difficult to thoroughly characterize. The collaboration will also leverage the global capabilities and infrastructure of Sandoz for developing, manufacturing, and marketing complex drugs.”

This plainly rules out the simpler protein drugs such as the insulins and interferons.

In guessing which of the complex protein drugs M178 might be, it helps to examine the US patent-expiration dates of the various large-selling biologics (see table below). However, the fact that there is no Orange Book for biologics renders this exercise somewhat imprecise.



Remicade and Enbrel would seem to fit the bill, as does Neulasta (US patent expiration in 2015—thanks, genisi).